- Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun
NEW YORK, NY, December 15, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives.
The following promotions are effective January 1, 2023, and each individual will join the Senior Leadership Committee:
- Sara Klymkowsky will be promoted to Senior Vice President, Research & Investments. Sara has been an integral member of the Research & Investments team since joining Royalty Pharma in 2012. She has played a key role in executing many of Royalty Pharma’s most important transactions, including investments in the Vertex cystic fibrosis franchise, Tysabri and Trelegy.
- Brienne Kugler will be promoted to Senior Vice President, Research & Investments. Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014. She has played a major role in executing many of Royalty Pharma’s most important transactions, including multiple Biohaven investments, Tremfya and Evrysdi.
- Alessandra Sassun will be promoted to Senior Vice President, Head of Human Capital. Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management.
“We are delighted to announce the promotions of Sara, Brienne and Alessandra as well as their addition to Royalty Pharma’s Senior Leadership Committee,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “ Sara and Brienne have been exceptionally strong contributors to Royalty Pharma’s success, and have led the sourcing, engagement, diligence, and execution of many of our most important royalty transactions. Alessandra brings deep experience and diverse perspectives from her many years overseeing human capital at leading investment firms. I am confident our strengthened leadership team is well positioned to execute on our mission of accelerating innovation in life sciences and transforming patient lives while delivering value for all of our stakeholders.”
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates.
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Royalty Pharma’s own internal estimates and research. While Royalty Pharma believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772